Takeshi Yamamoto Selected Research

Dantrolene (Dantrium)

1/2022	Stabilization of RyR2 maintains right ventricular function, reduces the development of ventricular arrhythmias, and improves prognosis in pulmonary hypertension.
9/2020	Dantrolene prevents hepatic steatosis by reducing cytoplasmic Ca2+ level and ER stress.
1/2020	Dantrolene prevents ventricular tachycardia by stabilizing the ryanodine receptor in pressure- overload induced failing hearts.
1/2020	Stabilizing cardiac ryanodine receptor prevents the development of cardiac dysfunction and lethal arrhythmia in Ca2+/calmodulin-dependent protein kinase IIδc transgenic mice.
8/2011	Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia.
11/2010	Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
5/2009	Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor.
9/2002	Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Yamamoto Research Topics

Disease

32	Heart Failure 01/2022 - 02/2004
18	Type 2 Diabetes Mellitus (MODY) 01/2022 - 07/2006
17	Food Hypersensitivity (Food Allergy) 01/2021 - 06/2007
15	Myocardial Infarction 01/2022 - 06/2004
12	Ventricular Tachycardia 01/2022 - 06/2005
12	Cardiac Arrhythmias (Arrythmia) 01/2022 - 09/2005
10	Polymorphic catecholergic ventricular tachycardia 01/2019 - 09/2005
9	Body Weight (Weight, Body) 08/2022 - 01/2016
8	Colitis 01/2022 - 01/2010
8	Pulmonary Embolism 12/2015 - 10/2003
7	ST Elevation Myocardial Infarction 05/2022 - 04/2006
7	Hemorrhage 09/2021 - 10/2003
7	Inflammation (Inflammations) 01/2021 - 09/2007
7	Infections 04/2020 - 10/2009
7	Malignant Hyperthermia 01/2020 - 01/2002
6	Neoplasms (Cancer) 12/2021 - 11/2009
6	Aortic Dissection 11/2021 - 04/2005
6	Shock 10/2021 - 06/2004
5	Thrombosis (Thrombus) 01/2022 - 02/2011
5	Acute Coronary Syndrome 11/2021 - 07/2005
5	Fibrosis (Cirrhosis) 01/2021 - 09/2006
5	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2021 - 06/2004
5	Diarrhea 01/2019 - 03/2002
5	Hypertension (High Blood Pressure) 01/2019 - 09/2007
4	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 01/2016
4	Starvation 01/2019 - 01/2016
4	Cardiogenic Shock 06/2015 - 10/2003
4	Pulmonary Edema 09/2014 - 01/2006
3	Hypertrophy 07/2022 - 12/2018
3	Rectal Neoplasms (Rectal Cancer) 06/2022 - 12/2021
3	Proteinuria 12/2021 - 01/2010
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 09/2007
3	Ischemia 10/2020 - 01/2012
3	Immune System Diseases (Immune Disorders) 01/2020 - 01/2014
3	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2020 - 01/2018
3	Ventricular Fibrillation 12/2019 - 06/2004
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2019 - 08/2008
3	Heart Diseases (Heart Disease) 10/2017 - 03/2002
3	Dyslipidemias (Dyslipidemia) 11/2016 - 07/2006
3	Fever (Fevers) 01/2016 - 10/2010
3	Renal Insufficiency (Renal Failure) 11/2013 - 08/2006
2	Dry Eye Syndromes (Dry Eye Syndrome) 01/2022 - 09/2014
2	Corneal Injuries 01/2022 - 09/2014

Drug/Important Bio-Agent (IBA)

31	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2022 - 01/2002
10	Proteins (Proteins, Gene)FDA Link 08/2022 - 09/2005
9	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2021 - 04/2010
9	Pharmaceutical PreparationsIBA 01/2021 - 09/2002
8	Dantrolene (Dantrium)FDA LinkGeneric 01/2022 - 09/2002
7	Glucose (Dextrose)FDA LinkGeneric 10/2020 - 12/2016
6	Biomarkers (Surrogate Marker)IBA 12/2021 - 09/2007
5	empagliflozinIBA 01/2022 - 10/2018
5	Dextran SulfateIBA 09/2021 - 11/2014
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2016
5	Adenosine Triphosphate (ATP)IBA 01/2021 - 11/2008
5	kakkon-toIBA 01/2020 - 01/2009
5	Messenger RNA (mRNA)IBA 01/2020 - 01/2013
5	LDL CholesterolIBA 11/2017 - 06/2007
4	SolutionsIBA 01/2022 - 03/2002
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 10/2018
4	Therapeutic UsesIBA 01/2022 - 01/2009
4	CytokinesIBA 01/2022 - 01/2006
4	CatecholaminesIBA 01/2022 - 01/2016
4	AntigensIBA 01/2021 - 04/2008
4	Triglycerides (Triacylglycerol)IBA 01/2021 - 07/2006
4	Insulin (Novolin)FDA Link 10/2020 - 07/2006
4	Amino Acids FDA Link 01/2020 - 11/2010
4	Epinephrine (Adrenaline)FDA LinkGeneric 01/2020 - 11/2010
4	EnzymesIBA 01/2020 - 09/2006
4	CreatinineIBA 10/2019 - 08/2006
4	oxidized low density lipoproteinIBA 11/2017 - 07/2006
4	CalciumIBA 12/2012 - 11/2008
4	Peptides (Polypeptides)IBA 09/2005 - 01/2002
3	Green Fluorescent ProteinsIBA 07/2022 - 01/2016
3	Hyaluronic Acid (Hyaluronan)IBA 01/2022 - 01/2008
3	Nicotine FDA Link 01/2022 - 01/2014
3	OxazoloneIBA 01/2022 - 01/2010
3	Cholinergic Agents (Cholinergics)IBA 01/2022 - 11/2008
3	Drinking WaterIBA 09/2021 - 01/2017
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021 - 01/2016
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 10/2017
3	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021 - 04/2017
3	Sirolimus (Rapamycin)FDA Link 01/2021 - 01/2019
3	Glucagon (Glukagon)FDA Link 12/2019 - 01/2013
3	Liraglutide FDA Link 02/2019 - 12/2016
3	Brain Natriuretic Peptide (Natrecor)FDA Link 02/2019 - 08/2006
3	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2018 - 10/2003
3	InflammasomesIBA 05/2017 - 07/2010
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2016 - 06/2007
3	TroponinIBA 12/2015 - 07/2005
3	Neurotransmitter Agents (Neurotransmitter)IBA 01/2014 - 11/2008
2	Castor Oil (Oil, Castor)IBA 01/2022 - 09/2014
2	Methylene Blue (Methylthioninium Chloride)FDA Link 01/2022 - 09/2014

Therapy/Procedure

23	Therapeutics 05/2022 - 03/2002
7	Catheters 01/2022 - 10/2003
6	Percutaneous Coronary Intervention 03/2022 - 06/2006
6	Thrombectomy 01/2022 - 05/2004
4	Extracorporeal Membrane Oxygenation 10/2021 - 01/2006
3	Drug Therapy (Chemotherapy) 06/2022 - 01/2012
3	Mechanical Ventilators (Ventilator) 09/2021 - 01/2009
3	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 11/2016 - 06/2004